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Summary
Background—Adenoviral vector-mediated gene therapy might have potential for long-term
correction of the monogenic disease hemophilia A.
Objective—In this study, we tested the efficacy of administering a helper-dependent adenoviral
vector (HDV) designed for maximal liver-restricted canine factor VIII (cFVIII) expression on
three out-bred hemophilia A dogs.
Methods—Three FVIII-deficient animals from the University of North Carolina colony were
injected with 1 × 1012 (Dog A), and 3 × 1012 (Dog B and C) vp kg−1 helper-dependent adenoviral
vector, and we performed systematic analysis of toxicity, persistence of therapeutic gene
expression, and molecular analysis of gene transfer.
Results—We observed acute dose-dependent elevation in liver enzymes and thrombocytopenia
after injection, although both were transient and resolved within 2 weeks. The whole blood
clotting time (WBCT), plasma FVIII concentration, FVIII activity, and activated partial
thromboplastin time in all animals improved significantly after treatment, and two animals
receiving a higher dose reached near normal WBCT with low-level FVIII activity until terminal
sacrifice at 3 months, and 2 years. Importantly, the treated dogs suffered no bleeding events after
injection. Moreover, we observed persistent vector-specific DNA and RNA in liver tissue
collected from one high-dose animal at days 18 and 79, and could not detect the formation of
inhibitory antibodies.
Conclusion—Although vector-associated toxicity remains an obstacle, a single injection of
HDV led to long-term transgene expression and vector persistence in two FVIII-deficient animals
with conversion of their severe phenotype to a moderate one.
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Introduction
A deficiency in coagulation factor (F) VIII results in the bleeding disorder, hemophilia A
(HA) [1]. Recombinant and plasma-derived FVIII protein therapy can effectively treat
spontaneous bleeding in the joints, muscles and internal organs, leading to prolonged life
expectancy [2–4]. However, this mode of therapy is costly, requires repeated administration,
and is rendered ineffective by the emergence of FVIII-specific antibodies [5,6]. Gene
therapy strategies are attractive treatment options because of the potential for sustained
production of FVIII.
Adenoviral vectors can accommodate large cDNAs and exhibit efficient transduction of both
dividing and non-dividing cells. Initial studies using adenovirus in hemophilic dogs were
conducted with the human FVIII cDNA but expression was short term [7]. However,
biphasic toxicity of earlier generation vectors (deleted for some, but not all, of the native
viral coding DNA sequences) was likely responsible for the short-term expression [8,9].
Recent studies concluded that adenoviral vectors devoid of all viral coding sequences
(Helper Dependent Vectors, HDV) alleviate the biphasic toxicity associated with low-level
expression of viral genes [10–12]. Moreover, recent works suggest pegylation of virions
[13–15], or possibly surgical hepatic isolation [16] could limit the dose requirement and
thereby reduce the systemic toxicity associated with HDV administration. Therefore,
combining the limited toxicity of HDV with advances in production, purification, and vector
design suggests HDV-mediated gene transfer warrants further investigation for the treatment
of HA [17].
When HDVs were used to deliver the canine FVIII transgene to a dog model of HA, plasma
FVIII levels decreased significantly from peak levels over the course of a few weeks [18].
Although the reason for this is unclear, one possibility is that vector DNA remains episomal
in transduced cells, and vector genome loss during cell division could account for the loss of
plasma FVIII protein [19].
We investigated the efficacy of HDV-mediated gene therapy in the University of North
Carolina canine model of severe HA [20]. We observed long-term phenotypic correction of
FVIII-dependent clotting function, despite a significant decrease in plasma FVIII levels over
several weeks. To determine whether this was because of vector genome loss, we performed
liver biopsy on an HDV-treated dog at two separate time-points correlating with the peak of
plasma FVIII and after it had decreased to minimal levels. The data show long-term
presence of HDV-specific DNA and RNA correlates with partial WBCT and APTT
correction, as well as the absence of spontaneous bleeding episodes.
Materials and methods
Preparation of helper-dependent Ad vector HDV-PEPCK/BDD-cFVIII/WPRE
The vector (HDV-PEPCK/BDD-cFVIII/WPRE, Fig. 1A) was prepared using the reagents
and methods described in detail elsewhere [10,17]. Briefly, canine B-domain deleted-FVIII
cDNA was cloned into the NotI restriction site of shuttle plasmid pGem7-PEPCK-WPRE.
The shuttle plasmid contained the rat phosphoenolpyruvate carboxykinase (PEPCK)
promoter with downstream elements in the following order: intronic DNA, multicloning site,
woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), and a human
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growth hormone poly-A [21]. The PEPCK promoter is tissue restricted and expresses largely
in hepatocytes [22]. The WPRE element increases mRNA levels in tissues transduced with
viral gene transfer vectors [21,23–25]. AscI digestion released the transgene cassette from
the shuttle plasmid and was inserted into a unique AscI site on the pΔ28E4 HDV plasmid
[26]. Virion DNA was analyzed by Southern blot and the level of helper virus contamination
was determined by phosphorimager analysis as described [17]. Physical titer was determined
spectrophotometrically and expressed as vector particles per milliliter (vp mL−1). Average
titer for vector preparations was 7 × 1012 vp mL−1.
Animal procedures
The animals used for these experiments were mixed breed dogs from the University of
North Carolina at Chapel Hill colony. Animals were sedated with ketamine prior to the
procedure. Next, HDV was diluted in phosphate buffered saline (PBS), and delivered by
forelimb vein catheter over 50 min. The catheter was flushed with PBS following vector
administration. During the administration of vector, no transfusion of cryoprecipitate
occurred. Dog C underwent liver biopsies under general anesthesia via midline abdominal
incision with direct inspection of the liver. Normal canine plasma was given prior to the
procedure for hemostasis. Two biopsy samples were taken on day 18, and again on day 79
from two different areas of the liver. Separate DNA preparations are indicated in the figures
as 18-1 and 18-2, 79-1 and 79-2, for each independent biopsy site.
All animals were treated in accordance with the standards set in Guide for the Care and Use
of Laboratory Animals (National Institute of Health no. 85–23). The Institutional Animal
Care and Use Committee approved all experiments.
Toxicity assays
All blood samples for toxicity and hemostatic measurements were obtained at indicated
time-points by cephalic vein phlebotomy. Serum was prepared to quantify liver enzymes and
other liver function studies including aspartate aminotransferase (AST), and alanine
aminotransferase (ALT) (ANTECH Inc., Cary, NC, USA). Complete blood counts were
performed on ethylenediaminetetra-acetic acid (EDTA)-anticoagulated blood with a cell
counter (Heska Co., Fort Collins, CO, USA) calibrated for dogs.
Whole blood clotting times (WBCT)
This assay is performed by a two-tube procedure at 28 °C. One milliliter of whole blood is
distributed equally between two siliconized tubes (Vacutainer™, #6431, Becton-Dickinson,
Rutherford, NJ, USA). The first tube is tilted every 30 s. After a clot forms, the second tube
is tilted and observed every 30 s. The endpoint measurement is the clotting time of the
second tube. The WBCT was assayed prior to infusion of vector (baseline), at 1, 8, and 24 h,
and weekly thereafter.
Activated partial thromboplastin time (APTT)
Activated partial thromboplastin time was determined on plasma samples from the indicated
time-points by analysis in the ST4 coagulation instrument (Diagnostica Stago, Asnieres,
France) or the Multiple Discrete Analyzer (MDA) 180 (Organon Teknika, Durham, NC,
USA) that has the capacity to process rapidly a large number of samples. Whether APTTs
are determined on the ST4 coagulation instrument, or the Orgenon Teknika MDA 180, the
controls and reagents are of the same type. For the APTT test, mixtures consist of equal
portions of partial tromboplastin (Automated APTT, Bio-Mérieux, Durham, NC, USA),
0.025 M CaCl2, and citrated test plasma [27,28]. Normal canine reference plasma consists of
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pools from 5–10 normal dogs from our inbred colony and a reference range is established
for each preparation, usually 24–34 s.
Chromogenic assay for FVIII activity
Biologically active canine FVIII was measured in the dog plasma using the COATEST
chromogenic bioassay according to the manufacturer’s specifications (Coamatic assay for
FVIII, Chromogenix Instrumentation Laboratory from Milan, Italy; distributed by
Diapharma, Westchester, OH, USA). Standard curve, generated using pooled normal canine
reference plasma, was provided by Dr Nichols (University of North Carolina, Chapel Hill,
NC, USA).
ELISA assay for FVIII antigen
The FVIII enzyme-linked immunosorbent assay (ELISA) was performed according to
manufacturers protocol. (Affinity Biologicals, Ancaster, ON, Canada). Data represented as
percent level of pooled human plasma standard.
DNA and RNA preparation
Liver biopsies were collected and immediately frozen (−80 °C) at days 18 and 79
postinjection for dog C. DNA was extracted as described elsewhere so as to avoid
polymerase chain reaction (PCR) interference by hemoglobin [29]. Total genomic DNA was
then extracted by phenol–chloroform separation.
Control DNA was prepared from normal canine whole blood using the Puregene DNA
purification system (Gentra Systems, Minneapolis, MN, USA). Total RNA was isolated
from biopsied livers using Trizol™ (Invitrogen, Carlsbad, CA, USA) according to
manufacturer’s instructions. All nucleotide concentrations were determined with Pico Green
reagent (DNA), or Ribo Green (RNA) (Molecular Probes, Eugene, OR, USA) using a
Fluostar fluorescent plate reader (BMG Lab technologies GmbH, Durham, NC, USA)
according to manufacturer’s protocol.
Quantitative and semi-quantitative PCR
Forty nanograms of template DNA was added to each PCR reaction using AmpliTaq™ gold
thermostable polymerase. An initial activation cycle of 95 °C for 16 min was followed by 33
cycles at 95 °C, 52 °C, and 72 °C each at 30 s and a final extension cycle of 72 °C for 7 min.
Real-time PCR was conducted using a Roche Lightcycler and Roche LC FS DNA Master
SYBR Green I reaction chemistry (Roche, Indianapolis, IN, USA) according to
manufacturer instructions. Five nanograms of each sample was amplified for 45 cycles at 58
°C annealing temperature; otherwise, all PCR and melting curve profiles were performed
using default instrument parameters. WPRE-specific primers used for both semi-quantitative
PCR were: forward primer 5′-TCTCTTTATGAGGAGTTGTGGCCC-3′ reverse 5′-
ACTGACAATTCCGTGGTGTTGTCG-3′.
RT-PCR
qPCR was performed in a Roche Lightcycler 1.0 using Roche Lightcycler Faststart DNA
Master SYBR Green I chemistry using the following WPRE-specific primers: sense, 5′-
TCTCTTTATGAGGAGTTGTGGCCC-3′ and antisense, 5′-
ACTGACAATTCCGTGGTGTTGTCG-3′. Semi-quantitative PCR was performed using
equal quantities of cDNA for each sample in an MJ thermocycler by standard PCR
chemistry, using WPRE-specific primers with annealing at 62 °C, products were removed
before the plateau phase of PCR.
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Eight micrograms of genomic DNA was digested with XmaI, electrophoresed through a
0.8% agarose gel and transferred to a nylon membrane. The probe specific for the WPRE
sequence was prepared by excision from the shuttle plasmid followed by phenol–chloroform
extraction and ethanol precipitation. The purified probe was labeled with [α32P] dCTP by
random priming. Hybridization occurred at 65 °C as did successive washes with first 2.0X
SSC/0.1% SDS and then with 0.5 × SSC/0.1% SDS. Relative abundance of hybridized
fragments was detected by Phosphoimager analysis (Molecular Dynamics, Sunnyvale, CA,
USA).
Results
Analysis of helper-dependent adenoviral vectors
The HDV used in this study, HDV-PEPCK/BDD-cFVIII/WPRE, carries a liver-restricted
canine FVIII expression cassette and was produced as previously described [17]. Figure 1A
depicts an illustration of the vector genome. To confirm vector integrity, the HDV and the
helper-virus (HV) were digested with ApaLI, and the pΔ28E4-PEPCK/BDD-cFVIII/WPRE
plasmid (pHDV) from which the vector was derived was digested with PmeI and ApaLI, and
electrophoresed through a 1% agarose gel. No rearrangements were evident as the HDV and
plasmid were similar save for the presence of a 2.5 kb ApaLI–PmeI fragment bearing the
bacterial plasmid sequences in the pHDV lane (Fig. 1B arrowhead). This gel was transferred
to a nylon membrane, and Southern blot was performed using a probe specific to the
packaging signal (Fig. 1C). The degree of helper virus contamination was calculated as the
ratio of the signal from the helper virus band divided by the signal from the HV band plus
helper-dependent vector band [HV/(HV + HDAd)] in the helper-dependent vector lane. The
Southern blot was quantified by phosphoimager analysis, and HV contamination was
approximately < 0.2% (Fig. 1C).
Transient acute toxicity associated with HDV administration
Three dogs replicating the severe HA phenotype were injected via the forelimb vein with
HDV-PEPCK/BDD-cFVIII/WPRE (Fig. 1A). Dog A received 1 × 1012 vector particles per
kilogram (vp kg−1) and dogs B and C received 3 × 1012 vp kg−1. Laboratory measurements
of acute toxicity were assessed throughout, and in the days following vector infusion. The
animal receiving 1 × 1012 vp kg−1 (dog A) showed marginal changes in hepatic
transaminases (Fig. 2A,B) and transiently decreased platelet counts, but did not deviate from
the normal range (Fig. 2C), suggesting the lower 1 × 1012 vp kg−1 dose results in transient
hematological toxicity but not liver-associated toxicity. Two animals receiving 3 × 1012 vp
kg−1 (dogs B and C) showed an acute transient elevation of hepatic transaminases that
returned to baseline by 72 h after injection (Fig. 2A,B). Platelet levels dropped from 400 000
to 100 000 mm−3 in dog B, and from 200 000 to 59 000 mm−3 in dog C by day 2, and
returned to the normal range by day 7 in dog B, and by day 16 in dog C (Fig. 2C). The
observed change in liver transaminases and drop in platelet levels are, in general, consistent
with previous studies [8,10–12,30]. As the change in liver transaminases and platelet levels
were not consistent with severe liver damage or bleeding, neither dog required infusion of
normal canine plasma, although this was not the case in a similar study [31], and as each
parameter resolved after a few days, we conclude that both doses were not associated with
life-threatening toxicity in this experiment. Importantly, clinical parameters of toxicity were
monitored in dog B for 2 years after vector administration with no significant changes,
indicating the absence of chronic toxicity.
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Phenotypic correction of bleeding disorder in FVIII-deficient dogs
To determine whether the HDV- PEPCK/BDDcFVIII/WPRE vector would result in
phenotypic correction of FVIII deficiency, WBCT was followed in the three animals after
vector administration (Fig. 3A). In dog A, WBCT decreased from a baseline of 45–15 min, 2
weeks after vector delivery (Fig. 3A, boxes). The animal was followed until terminal
sacrifice at 24 weeks at which time the WBCT was 28 min. The WBCT of dog B decreased
from 40 to 8 min after 2 weeks postinjection (Fig. 3A, circles). This animal was followed for
2 years until terminal sacrifice, and maintained WBCTs in the 14–16 min range. Dog C
received the same dose of vector as dog B and the WBCT of dog C decreased from 45.5 min
to a minimum of 10.5 min on day 16, and maintained WBCT in the 10–16 min range until
sacrifice at 12 weeks (Fig. 3A, triangles).
Likewise, APTT measurements for each dog decreased from the preinjection levels of 61,
64, and 66 s, for dogs A, B, and C, respectively (Fig. 3B). Although APTT for dog A were
followed for only 20 days (Fig. 3B, boxes), dogs B and C were measured for 77 and 233
days, and the lowest APTT values were observed on days 11 and 4 for dogs B and C,
respectively, when it dropped to nearly 45 s (Fig. 3B, circles and triangles). It is important to
note that a significantly reduced APTT was observed on day 233 for dog B (53 s). However,
the normal APTT for wild-type dogs is between 36 and 39 s [32], and thus we did not
observe complete correction of this parameter in any of the dogs. Regardless, this is the
longest observed correction of WBCT after a single HDV gene therapy treatment.
Moreover, as untreated HA dogs would be expected to have ~5 bleeding events per year
requiring plasmaphoresis, and as both dogs receiving the higher dose of HDV-PEPCK/
BDD-cFVIII/WPRE did not manifest any bleeding episodes, significant clinical
complications of the HA were avoided. Taken together, these data indicate that the higher
dose animals converted from severe-to-moderate hemophilia after HDV infusion.
FVIII activity and FVIII plasma concentration analysis
Plasma levels of the canine FVIII transgene product were determined by both FVIII ELISA
and chromogenic bioassay (COATEST) (Fig. 4). Prior to treatment, all dogs had
undetectable plasma FVIII as measured by either COATEST or antigen ELISA. We
measured FVIII activity at peak levels of 4% on day 7 that quickly fell below detectable
levels by day 12 in dog A (Fig. 4A, boxes), which corresponded to a plasma FVIII
concentration peak level of 1.3% normal on day 8 (Fig. 4B, boxes), and then declined to <
1%, 43 days after vector administration. In summary, dog A received the lowest dose tested
(1 × 1012 vp kg−1) and achieved detectable, albeit transient FVIII concentrations which
correlated with significant decrease in WBCT but not APTT, transient thrombocytopenia,
and modest acute liver toxicity. These data highlight the importance of overcoming the dose
dependent effect of systemic adenoviral injection in order to achieve sufficient FVIII protein
expression for long-term therapy.
In dog B, we observed peak activity of 84% normal by COATEST at 14 days that decreased
and stabilized around 3–6% normal activity until terminal sacrifice on day 724 (Fig. 4A,
circles). Dog B also peaked in detectable antigen level on day 14, reaching 70% of the
normal control, and nominal levels of over 1% were detected at days 119, 162, 233, and 519
(Fig. 4B circles). In dog C, we observed peak activity of 54% on day 16 that decreased and
remained detectable for 79 days until terminal sacrifice. We noted variable percentages of
normal FVIII levels in the two dogs receiving the same dose (Compare Fig. 4B circles and
triangles). We speculate that the discrepancy between dogs B and C may be because of
inter-animal variability, or possibly a reflection of the relative differences in infectivity in
the vector preparations used for each dog. Nevertheless, both levels were sufficient to
substantially reduce the WBCT defect long term (Fig. 3, triangles, 79 days until terminal
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sacrifice, and circles, 2 years and terminal sacrifice). These WBCTs are consistent with the
relative effects of low levels of FVIII (Supplemental Fig. 1A). Taken together, these data are
consistent with the correlation of WBCT and FVIII activity in the canine model, where
minimal amounts of FVIII activity are sufficient to partially correct WBCT.
Long-term persistence of vector genome and message after HDV administration
We sought to determine if vector genome loss was a major factor in the precipitous decline
of plasma FVIII activity from weeks 2–12. Liver biopsy tissue from dog C was collected at
day 18 postvector administration and at day 79. These time-points correspond to the peak of
plasma FVIII activity (54% normal at day 16, Fig. 4, triangles) and to the time when activity
had fallen to nearly 3% normal (day 77).
To determine whether the decrease of plasma FVIII activity over time could be explained by
loss of vector genome, total DNA was isolated from the days 18 and 79 liver samples.
Genomic Southern analyses were performed using a vector-specific probe to the WPRE
sequence. A canine β-actin probe was used to control for DNA input. DNA isolated from the
blood of an unaffected dog was used as control. We observed an approximate 2-fold
decrease of vector-specific DNA at the later time-point (Fig. 5A, compare lanes 18-1 and
18-2, to lanes 79-1 and 79-2). This result was confirmed by semi-quantitative PCR, which
showed a similar 2-fold decrease at the later time-point (Fig. 5B), as well as by real-time
PCR (data not shown). The lack of a band in the control lane (Fig. 5B lane C) of the
appropriate size indicates that there was no cross-reactivity with normal canine DNA and the
WPRE-specific probe, and thus the probe is specific to the HDV intervention.
Given the persistence of vector genome, we hypothesized that vector-specific message was
also persistent in the biopsy tissue. We measured total RNA by RT PCR using a probe
against the WPRE element because it was unique to the vector RNA. On qualitative
analysis, we observed WPRE-specific RNA in liver tissue isolated from dog C collected on
days 18, and 79, but not liver from a control uninjected FVIII-deficient dog from the same
colony (Fig. 5C, inset). Similarly, when the cDNA samples were analyzed by real-time
PCR, we observed a 1.89 cycle difference in crossing points comparing day 18 (30.55
cycles) to day 79 (32.44 cycles). As the crossing point analysis is dependent upon the
concentration of input cDNA (determined by fluorometry and normalized for each sample),
we calculate a 3.8-fold decrease in RNA from days 18–79. This is on par with the decrease
observed in vector-specific DNA. Taken together, this data suggest that long-term vector
persistence, expression, and therapeutic effect are achievable, at least in this canine HA
model, after a single injection of HDV-PEPCK/BDD-cFVIII/WPRE.
Discussion
A similar recent study tested the feasibility of systemic injection of HDV-expressing cFVIII
into a FVIII-deficient canine model [18]. Of note, the animal colony, vector construct
(including promoter), dose of vector (1.25–2 vs. 3 × 1012 vp kg−1), resulting FVIII
expression maximum (10–20% vs. 84%), and duration of analysis (1% at day 168 vs. 3.5%
at day 724) differed from the current study. In addition, one animal in the Brown et al. study
received 2 × 1012 vp kg−1, and reached 20% FVIII activity, but soon developed
immunologic clearance of antigen. Neither the 1 × 1012 vp kg−1 nor the two 3 × 1012 vp
kg−1 animals in the present study developed inhibitory antibodies (data not shown). We
speculate that these observed differences are accounted for by variability between the animal
colonies, as well as differences in vector construction, amplification and purification, and
the experimental limitations inherent in small numbers used in large animal experiments.
Hence, each experimental condition substantially contributes to the overall preclinical
experience of HDV and canine HA.
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Another study observed loss of therapeutic antigen over time after a HDV expressing cFIX
was administered to hemophilia B dogs [33]. As HDV genomes exist as episomal DNA, it
was postulated that loss of vector genomes over time might explain the loss of transgene
production. To directly test this, we performed survival liver biopsies on a HDV-treated dog
at times correlating with high and low levels of plasma FVIII. We determined that vector
genome loss could not explain the magnitude of decrease in FVIII. We also observed
persistence of vector-specific mRNA. In addition, dog B doubled in size from the time of
injection (9.4 kg) until terminal sacrifice (21 kg), yet the single injection of HDV was
responsible for a 2-year conversion from severe-to-moderate hemophilia. Together, these
data strongly suggest that neither animal growth, tissue turn-over, nor promoter shut-off is
responsible for the decrease in FVIII antigen.
Despite these data, the putative FVIII clearance mechanism remains unknown. Indeed, our
attempts to identify cFVIII-specific antibodies which might cause the observed decline in
circulating FVIII were unsuccessful by both Western analyses, and ELISA (data not shown),
although this was primarily limited by the lack of sufficient canine-specific reagents.
These studies underscore the ‘threshold effect’ evident after systemic adenovirus injection,
where linear dose escalation does not correlate with protein expression [34]. Moreover, it is
likely that the therapeutic threshold is different across species. In fact, mice and non-human
primates are apparently more tolerant to high doses of vector compared with humans, and
more than one human trial was abruptly halted because of vector-associated toxicity to 50–
100-fold less virus than the dose tested in the present study [35]. Although the dose tested
was not clinically relevant per se, the observation that vector genome and expression can
persist for at least 2 years is itself important, and unprecedented with other adenoviral
vectors in this model. Moreover, it suggests that if innate toxicity to adenovirus is overcome,
relatively long-term clinical effect can be achieved without risk of genotoxicity.
Methods that restrict viral exposure to specific organs [16] and PEG-ylation strategies that
shield the virus from the immune system [13–15] are a few examples of current efforts to
overcome the threshold effect, and hence, dose-related acute toxicity.
Clearly, further studies are needed to elucidate and ultimately avoid all of the potential toxic
and immunologic responses to HDV-mediated gene therapy for HA. Encouragingly, the
production of cFVIII from this HDV construct was sufficient to overcome a putative antigen
clearance mechanism, and confer long-term reduction in WBCT. Thus, if the dose threshold
were to be overcome, then HDV gene transfer for FVIII deficiency should result in long-
term therapeutic benefit.
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Construction and analysis of helper-dependent adenoviral vector HDV-PEPCK/BDD-
cFVIII/WPRE. (A) Schematic of DNA used to construct HDV-PEPCK/BDD-cFVIII/
WPRE. ψ is the viral packaging signal, and the inverted terminal repeats are the only native
viral DNA in the vector. Stuffer DNA was derived from intronic human sequences [26]. The
expression cassette contains the phosphoenolpyruvate carboxykinase (PEPCK) promoter,
the ApoA1 intron, canine B-domain-deleted factor VIII cDNA, woodchuck hepatitis virus
post-transcriptional regulatory element (WPRE), and a human growth hormone poly-A [21].
(B) ApaLI digest of helper-virus (HV), helper-dependent adenoviral vector (HDV), and
PmeI/ApaLI digest of the cloning vector (pHDV), demonstrating no gross rearrangements,
occurred during production. Arrowhead indicates plasmid-derived sequence. (C) Southern
analysis of the same filter probed for the adenoviral packaging signal. In the HDV lane,
comparison of the vector signal at 1.7 kb with the fragment containing the packaging signal
at 0.6 kb by phosphoimager analysis reveals < 0.2% HV contamination.
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Toxicity profiles in two hemophilic dogs treated with HDV-PEPCK/BDDcFVIII/WPRE.
Plasma was collected from the dogs at the indicated times prior to and after vector
administration. (A) aspartate aminotransferase aspartate aminotransferase and (B) alanine
aminotransferase analyses of three dogs receiving either 1 × 1012 vp kg−1 (dog A) or 3 ×
1012 vp kg−1 (dogs B and C) HDV on day zero. (C) Platelet levels were measured for each
dog throughout vector administration.
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Whole blood clotting time (WBCT) and activated partial thromboplastin time (APTT) after
injection of HDV-PEPCK/BDD-cFVIII/WPRE. Blood samples were measured periodically
for WBCT and APTT as described in Materials and methods. (A) WBCT was monitored for
the indicated time. Dog A received 1 × 1012 vp kg−1, and dogs B and C received 3 × 1012 vp
kg−1. WBCT of dog B was measured for 2 years, and dog C for 79 days until terminal
sacrifice. Normal WBCT = 8–12 min.
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Plasma factor VIII (FVIII) activity in canine hemophilia A dogs treated with HDV-PEPCK/
BDDcFVIII/WPRE. Each dog was administered HDV on experimental day 0. Dog A
received 1 × 1012 vp kg−1 body weight and dogs B and C each received 3 × 1012 vp kg−1
body weight. Periodic blood samples were collected and percent normal FVIII activity was
measured by COATEST assay (A) and FVIII antigen level was measured by enzyme-linked
immunosorbent assay (B). Dotted line represents lower limit of detection.
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Persistence of vector-specific DNA in liver after administration of HDV-PEPCK/BDD-
cFVIII/WPRE. (A) Vector-specific Southern blot. Genomic DNA from days 18 and 79 liver
biopsy tissue was probed with vector-specific WPRE element. Control is normal canine
genomic DNA. (B) Semi-quantitative polymerase chain reaction (PCR) with WPRE and
beta-actin-specific primers. BA is β actin control, C is DNA derived from a normal dog, W
is WPRE primer run in water, and BA* is β actin-specific primers run in water. (C) RT-PCR
and qualitative RT-PCR from days 18 and 79 liver biopsy tissue were performed with
vector-specific WPRE primers. Naïve indicates an untreated FVIII-deficient animal, W is
water control.
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